vs
Amphastar Pharmaceuticals, Inc.（AMPH）とCSG SYSTEMS INTERNATIONAL INC（CSGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 2.2%、差は11.2%）。CSG SYSTEMS INTERNATIONAL INCの前年同期比売上増加率が高い（2.0% vs -1.8%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $24.6M）。過去8四半期でCSG SYSTEMS INTERNATIONAL INCの売上複合成長率が高い（4.6% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
AMPH vs CSGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $323.1M |
| 純利益 | $24.4M | $7.0M |
| 粗利率 | 46.8% | 50.0% |
| 営業利益率 | 19.4% | 9.0% |
| 純利益率 | 13.3% | 2.2% |
| 売上前年比 | -1.8% | 2.0% |
| 純利益前年比 | -35.7% | -79.7% |
| EPS（希薄化後） | $0.51 | $0.24 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $323.1M | ||
| Q3 25 | $191.8M | $303.6M | ||
| Q2 25 | $174.4M | $297.1M | ||
| Q1 25 | $170.5M | $299.5M | ||
| Q4 24 | $186.5M | $316.7M | ||
| Q3 24 | $191.2M | $295.1M | ||
| Q2 24 | $182.4M | $290.3M | ||
| Q1 24 | $171.8M | $295.1M |
| Q4 25 | $24.4M | $7.0M | ||
| Q3 25 | $17.4M | $20.5M | ||
| Q2 25 | $31.0M | $12.3M | ||
| Q1 25 | $25.3M | $16.1M | ||
| Q4 24 | $38.0M | $34.5M | ||
| Q3 24 | $40.4M | $19.1M | ||
| Q2 24 | $37.9M | $13.8M | ||
| Q1 24 | $43.2M | $19.5M |
| Q4 25 | 46.8% | 50.0% | ||
| Q3 25 | 51.4% | 48.1% | ||
| Q2 25 | 49.6% | 49.5% | ||
| Q1 25 | 50.0% | 48.4% | ||
| Q4 24 | 46.5% | 51.3% | ||
| Q3 24 | 53.3% | 49.4% | ||
| Q2 24 | 52.2% | 47.3% | ||
| Q1 24 | 52.4% | 46.5% |
| Q4 25 | 19.4% | 9.0% | ||
| Q3 25 | 13.2% | 10.0% | ||
| Q2 25 | 24.2% | 10.0% | ||
| Q1 25 | 21.9% | 9.8% | ||
| Q4 24 | 24.2% | 13.4% | ||
| Q3 24 | 29.8% | 10.8% | ||
| Q2 24 | 30.3% | 8.8% | ||
| Q1 24 | 27.9% | 10.8% |
| Q4 25 | 13.3% | 2.2% | ||
| Q3 25 | 9.0% | 6.7% | ||
| Q2 25 | 17.8% | 4.1% | ||
| Q1 25 | 14.8% | 5.4% | ||
| Q4 24 | 20.4% | 10.9% | ||
| Q3 24 | 21.1% | 6.5% | ||
| Q2 24 | 20.8% | 4.8% | ||
| Q1 24 | 25.1% | 6.6% |
| Q4 25 | $0.51 | $0.24 | ||
| Q3 25 | $0.37 | $0.73 | ||
| Q2 25 | $0.64 | $0.44 | ||
| Q1 25 | $0.51 | $0.57 | ||
| Q4 24 | $0.74 | $1.20 | ||
| Q3 24 | $0.78 | $0.67 | ||
| Q2 24 | $0.73 | $0.48 | ||
| Q1 24 | $0.81 | $0.68 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $180.0M |
| 総負債低いほど良い | $608.7M | $539.5M |
| 株主資本純資産 | $788.8M | $283.7M |
| 総資産 | $1.6B | $1.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.90× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $180.0M | ||
| Q3 25 | $276.2M | $158.4M | ||
| Q2 25 | $231.8M | $145.9M | ||
| Q1 25 | $236.9M | $136.0M | ||
| Q4 24 | $221.6M | $161.8M | ||
| Q3 24 | $250.5M | $118.4M | ||
| Q2 24 | $217.8M | $110.4M | ||
| Q1 24 | $289.6M | $120.8M |
| Q4 25 | $608.7M | $539.5M | ||
| Q3 25 | $608.6M | $538.6M | ||
| Q2 25 | $607.7M | $537.8M | ||
| Q1 25 | $603.9M | $537.6M | ||
| Q4 24 | $601.6M | $538.5M | ||
| Q3 24 | $596.4M | $539.5M | ||
| Q2 24 | $586.9M | $540.5M | ||
| Q1 24 | $594.0M | $541.5M |
| Q4 25 | $788.8M | $283.7M | ||
| Q3 25 | $776.7M | $289.5M | ||
| Q2 25 | $757.5M | $290.7M | ||
| Q1 25 | $751.3M | $283.1M | ||
| Q4 24 | $732.3M | $282.6M | ||
| Q3 24 | $727.7M | $288.4M | ||
| Q2 24 | $713.3M | $273.3M | ||
| Q1 24 | $672.4M | $269.3M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B | ||
| Q1 24 | $1.6B | $1.3B |
| Q4 25 | 0.77× | 1.90× | ||
| Q3 25 | 0.78× | 1.86× | ||
| Q2 25 | 0.80× | 1.85× | ||
| Q1 25 | 0.80× | 1.90× | ||
| Q4 24 | 0.82× | 1.91× | ||
| Q3 24 | 0.82× | 1.87× | ||
| Q2 24 | 0.82× | 1.98× | ||
| Q1 24 | 0.88× | 2.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $59.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $55.8M |
| FCFマージンFCF / 売上 | 13.4% | 17.3% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 8.46× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $141.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $59.2M | ||
| Q3 25 | $52.6M | $47.9M | ||
| Q2 25 | $35.6M | $37.3M | ||
| Q1 25 | $35.1M | $11.5M | ||
| Q4 24 | $29.0M | $82.5M | ||
| Q3 24 | $60.0M | $39.5M | ||
| Q2 24 | $69.1M | $43.1M | ||
| Q1 24 | $55.3M | $-29.4M |
| Q4 25 | $24.6M | $55.8M | ||
| Q3 25 | $47.2M | $43.9M | ||
| Q2 25 | $25.0M | $34.6M | ||
| Q1 25 | $24.4M | $7.1M | ||
| Q4 24 | $16.6M | $76.6M | ||
| Q3 24 | $46.2M | $32.0M | ||
| Q2 24 | $63.1M | $38.8M | ||
| Q1 24 | $46.5M | $-34.1M |
| Q4 25 | 13.4% | 17.3% | ||
| Q3 25 | 24.6% | 14.5% | ||
| Q2 25 | 14.3% | 11.6% | ||
| Q1 25 | 14.3% | 2.4% | ||
| Q4 24 | 8.9% | 24.2% | ||
| Q3 24 | 24.1% | 10.8% | ||
| Q2 24 | 34.6% | 13.4% | ||
| Q1 24 | 27.1% | -11.6% |
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 1.5% | ||
| Q4 24 | 6.7% | 1.9% | ||
| Q3 24 | 7.2% | 2.5% | ||
| Q2 24 | 3.3% | 1.5% | ||
| Q1 24 | 5.1% | 1.6% |
| Q4 25 | 1.35× | 8.46× | ||
| Q3 25 | 3.03× | 2.34× | ||
| Q2 25 | 1.15× | 3.04× | ||
| Q1 25 | 1.39× | 0.71× | ||
| Q4 24 | 0.76× | 2.39× | ||
| Q3 24 | 1.48× | 2.07× | ||
| Q2 24 | 1.82× | 3.12× | ||
| Q1 24 | 1.28× | -1.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
